Tiziana Life Sciences Ltd
TLSAHealthcare|Biotechnology|GB
$0.69
+0.07 (+11.03%)
DCF Value
$0.01
Cash / Share
$0.02
Financials
Financial Snapshot
Market Cap
$87.7M
Enterprise Value
$85.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$38.0M
Cash & Investments
$3.2M
Net Cash
$2.2M
Free Cash Flow (TTM)
-$21.8M
Operating CF (TTM)
-$21.7M
Debt/Equity
-0.34
Cash Runway & Burn Rate
Cash on Hand
$3.2M
Quarterly Burn
$5.4M
Monthly Burn
$1.8M
Est. Runway
~0.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.7M | $48.0K | $5.3M | $153.0K | $65.8M | $42.2M | $18.1M | $1.2M | $3.7M | $4.0M | $3.2M | |
| Operating Cash Flow | -$5.6M | -$5.7M | -$4.6M | -$5.3M | -$8.8M | -$16.1M | -$16.0M | -$12.4M | -$1.2M | -$12.8M | -$21.7M | |
| Free Cash Flow | -$5.7M | -$5.7M | -$4.6M | -$5.3M | -$8.8M | -$16.1M | -$16.0M | -$12.4M | -$1.2M | -$12.9M | -$21.8M | |
| Capital Expenditure | -$38.5K | -$968.60 | $0.00 | -$3.0K | -$1.9K | -$16.3K | $0.00 | $0.00 | -$15.2K | -$21.0K | -$85.0K | |
| Financing Cash Flow | $1.3M | $1.2M | $10.1M | $1.3M | $54.1M | -$17.0K | -$44.8K | $31.7K | $3.6M | $10.0M | $20.2M |
R&D Spending
R&D (TTM)
$9.7M
R&D Intensity
—
R&D Growth vs Prior
-5.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.0M | $4.7M | $5.5M | $3.7M | $8.2M | $17.8M | $0.00 | $8.1M | $5.2M | $10.3M | $9.7M | |
| SG&A | $4.3M | $0.00 | $4.6M | $5.8M | $18.0M | $1.2M | $0.00 | $9.9M | $10.6M | $10.9M | $5.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $8.8K | $10.7K | $16.0K | $250.0K | $0.00 | $0.00 | $14.6M | $0.00 | $0.00 | $0.00 | $21.2M | |
| Gross Profit | -$8.8K | -$10.7K | -$16.0K | -$250.0K | $0.00 | $0.00 | -$14.6M | $0.00 | $0.00 | $0.00 | -$21.2M | |
| R&D | $3.0M | $4.7M | $5.5M | $3.7M | $8.2M | $17.8M | $0.00 | $8.1M | $5.2M | $10.3M | $9.7M | |
| SG&A | $4.3M | $0.00 | $4.6M | $5.8M | $18.0M | $1.2M | $0.00 | $9.9M | $10.6M | $10.9M | $5.9M | |
| Operating Income | -$7.3M | -$8.2M | -$9.9M | -$10.0M | -$38.1M | -$36.9M | -$14.6M | -$18.0M | -$15.8M | -$21.1M | -$41.8M | |
| Interest Expense | $9.9K | $8.7K | $12.0K | $93.6K | $435.3K | $237.4K | $7.0K | $10.0K | $6.0K | $18.0K | $6.0K | |
| Pretax Income | -$7.3M | -$8.3M | -$9.9M | -$10.1M | -$38.5M | -$36.0M | -$15.4M | -$17.2M | -$16.7M | -$18.4M | -$39.6M | |
| Net Income | -$7.2M | -$6.8M | -$8.0M | -$9.4M | -$35.5M | -$31.6M | -$15.4M | -$17.7M | -$11.9M | -$18.4M | -$38.0M | |
| EPS (Diluted) | -0.07 | -0.06 | -0.06 | -0.07 | -0.37 | -0.32 | -0.15 | -0.17 | -0.11 | -0.16 | -0.32 | |
| EBITDA | -$7.3M | -$8.2M | -$9.9M | -$9.7M | -$38.0M | -$35.6M | -$15.3M | -$17.1M | -$16.6M | -$18.2M | -$39.1M | |
| Shares Out. (M) | 106.40 | 116.98 | 136.48 | 136.48 | 97.31 | 97.93 | 101.53 | 102.47 | 106.67 | 118.28 | 127.87 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.7M | $48.0K | $5.3M | $153.0K | $65.8M | $42.2M | $18.1M | $1.2M | $3.7M | $4.0M | $3.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.0M | $1.8M | $6.9M | $1.1M | $70.2M | $48.7M | $24.3M | $7.3M | $7.5M | $8.6M | $9.4M | |
| Total Assets | $5.1M | $1.8M | $6.9M | $1.8M | $70.7M | $48.8M | $26.5M | $12.2M | $11.3M | $11.5M | $11.7M | |
| Total Current Liabilities | $1.7M | $3.5M | $6.7M | $5.6M | $8.0M | $7.5M | $6.7M | $6.5M | $7.3M | $11.2M | $13.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.7M | $3.5M | $6.4M | $6.0M | $8.3M | $7.5M | $6.9M | $6.6M | $7.3M | $11.4M | $14.4M | |
| Stockholders' Equity | $3.3M | -$1.7M | $518.1K | -$4.2M | $45.7M | $41.3M | $19.6M | $5.5M | $3.9M | $52.0K | -$2.7M | |
| Retained Earnings | $11.0M | -$29.8M | -$50.5M | -$43.1M | -$84.6M | -$108.1M | -$116.3M | -$133.7M | -$144.8M | -$44.4M | -$56.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.6M | -$5.7M | -$4.6M | -$5.3M | -$8.8M | -$16.1M | -$16.0M | -$12.4M | -$1.2M | -$12.8M | -$21.7M | |
| Capital Expenditure | -$38.5K | -$968.60 | $0.00 | -$3.0K | -$1.9K | -$16.3K | $0.00 | $0.00 | -$15.2K | -$21.0K | -$85.0K | |
| Free Cash Flow | -$5.7M | -$5.7M | -$4.6M | -$5.3M | -$8.8M | -$16.1M | -$16.0M | -$12.4M | -$1.2M | -$12.9M | -$21.8M | |
| Investing Cash Flow | -$276.9K | -$970.00 | $0.00 | -$3.0K | -$93.2K | $96.4K | -$3.3M | -$991.6K | -$56.7K | $3.0M | $2.9M | |
| Financing Cash Flow | $1.3M | $1.2M | $10.1M | $1.3M | $54.1M | -$17.0K | -$44.8K | $31.7K | $3.6M | $10.0M | $20.2M | |
| Issuance of Stock | $497.8K | $1.2M | $10.1M | $1.5M | $54.3M | $95.6K | $0.00 | $125.8K | $3.7M | $10.2M | $20.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $779.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$141.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M | |
| Net Change in Cash | -$6.0M | -$4.3M | $5.2M | -$4.0M | $48.3M | -$17.6M | -$19.6M | -$13.4M | $2.0M | $286.0K | $1.5M |
Dilution Tracker
Shares outstanding grew 21.6% over 5 years — significant dilution
Shares Outstanding
127M
5-Year Share Growth
+21.6%
Stock Issuance (TTM)
$20.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 106.40 | 116.98 | 136.48 | 136.48 | 97.31 | 97.93 | 101.53 | 102.47 | 106.67 | 118.28 | 127.87 | |
| Change vs Prior % | — | 9.9% | 16.7% | 0.0% | -28.7% | 0.6% | 3.7% | 0.9% | 4.1% | 10.9% | 8.1% | |
| Stock Issuance | $497.8K | $1.2M | $10.1M | $1.5M | $54.3M | $95.6K | $0.00 | $125.8K | $3.7M | $10.2M | $20.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -217.5% | 402.3% | -1540.1% | 224.0% | -77.8% | -76.5% | -78.7% | -319.6% | -301.4% | -35444.2% | 1869.1% | |
| ROA % | -142.7% | -369.7% | -115.5% | -518.0% | -50.3% | -64.7% | -58.2% | -145.2% | -105.1% | -160.3% | -216.0% | |
| ROIC % | -203.4% | 466.7% | -1684.9% | 320.9% | -54.1% | -76.1% | -73.2% | -311.0% | -276.8% | -4159.8% | 1284.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -21.5% | -49.9% | -1462.8% | 100.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 18.2% | -13.1% | -20.2% | -0.5% | -282.6% | 3.1% | 60.5% | -23.3% | 12.2% | -33.8% | |
| Net Income | 16.5% | 6.1% | -17.9% | -17.4% | -279.6% | 11.1% | 51.3% | -14.9% | 32.9% | -55.4% | |
| EPS (Diluted) | 26.6% | 14.5% | -1.0% | -17.3% | -439.4% | 13.5% | 53.1% | -13.3% | 35.3% | -45.5% | |
| Operating Cash Flow | 1.4% | -1.2% | 19.1% | -15.1% | -65.5% | -84.2% | 0.9% | 22.3% | 90.2% | -953.5% | |
| Free Cash Flow | 0.8% | -0.5% | 19.1% | -15.2% | -65.4% | -84.4% | 1.0% | 22.3% | 90.1% | -942.3% | |
| R&D Expense | -53.0% | 58.1% | 17.7% | -32.2% | 118.6% | 118.6% | -100.0% | 0.0% | -35.5% | 96.6% | |
| SG&A Expense | 86.2% | -100.0% | 0.0% | 24.9% | 210.4% | -93.6% | -100.0% | 0.0% | 7.0% | 2.7% | |
| Total Assets | -45.4% | -63.7% | 277.3% | -73.8% | 3808.0% | -30.9% | -45.8% | -54.0% | -7.4% | 1.9% | |
| Book Value / Share | -65.7% | -146.2% | 126.4% | -906.8% | 2193.4% | -34.3% | -54.3% | -72.0% | -31.7% | -98.8% | |
| Debt | 4.2% | 4.0% | 32.2% | 359.8% | -61.0% | 144.1% | -73.1% | -32.3% | -57.1% | 330.2% | |
| Diluted Shares | 13.7% | 9.9% | 16.7% | 0.0% | -28.7% | 0.6% | 3.7% | 0.9% | 4.1% | 10.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-32.06
10Y Low / Med / High2.28 / 18.87 / 3389.26
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.01
Cash / Share
$0.02
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -49.90 | -53.31 | -63.59 | -39.36 | -5.46 | -3.00 | -4.00 | -3.29 | -6.33 | -9.31 | -3.36 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 108.46 | -214.54 | 979.95 | -88.16 | 4.30 | 2.28 | 3.11 | 10.37 | 18.87 | 3389.26 | -32.06 | |
| EV/EBITDA | -48.76 | -43.87 | -50.81 | -38.07 | -3.46 | -1.49 | -2.81 | -3.29 | -4.25 | -9.50 | -3.43 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.64
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$20.5M | -$22.3M | -$22.7M |
| EPS | $-0.17 | $-0.19 | $-0.19 |
| # Analysts (EPS) | 1 | 1 | 1 |